Zosano Pharma Corporation (ZSANQ) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Fremont, CA, United States. The current CEO is Steven Lo.
ZSANQ has 40 full-time employees, listed on the Other OTC.
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
